Stephen Harrison
#86,877
Most Influential Person Now
British classical philologist
Stephen Harrison 's AcademicInfluence.com Rankings
Stephen Harrison literature Degrees
Literature
#3190
World Rank
#5396
Historical Rank
Classical Studies
#27
World Rank
#55
Historical Rank
Download Badge
Literature
Stephen Harrison 's Degrees
- Bachelors Classical Studies University of Oxford
- Masters Classical Studies University of Oxford
Why Is Stephen Harrison Influential?
(Suggest an Edit or Addition)According to Wikipedia, Stephen Harrison is a British classicist and a professor of Latin at the University of Oxford. He has published widely on the poetry of Virgil and Horace. Life and career Having read Classics at Balliol College, Harrison has taught Latin literature at the University of Oxford since 1987. In addition, he has been an occasional visiting professor at the universities of Copenhagen and Trondheim. While his research focuses on the poetry of Virgil and Horace, he has also written on the reception of classical literature and the Roman novel. He is a fellow of Corpus Christi College, Oxford.
Stephen Harrison 's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases (2018) (3932)
- Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. (2011) (1935)
- A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. (2006) (1610)
- Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. (2015) (1441)
- Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection (2010) (1279)
- Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. (2016) (741)
- Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis (2003) (699)
- Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease (2008) (695)
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial (2019) (620)
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. (2020) (504)
- The natural history of nonalcoholic fatty liver disease: a clinical histopathological study (2003) (499)
- A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis (2018) (481)
- Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial (2009) (433)
- Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis (2012) (290)
- NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial (2018) (281)
- Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial (2018) (280)
- FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study (2020) (267)
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial (2019) (262)
- Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (2018) (254)
- Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis (2017) (248)
- A Pilot Study Using Simvastatin in the Treatment of Nonalcoholic Steatohepatitis: A Randomized Placebo-controlled Trial (2009) (247)
- Features, diagnosis, and treatment of nonalcoholic fatty liver disease. (2012) (243)
- Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis (2009) (240)
- Benefits of lifestyle modification in NAFLD (2007) (240)
- Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes. (2015) (235)
- Pharmacotherapy for NASH: Current and emerging. (2018) (220)
- Ela fi branor , an Agonist of the Peroxisome Proliferator L Activated Receptor L a and L d , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening (220)
- Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials. (2020) (214)
- Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. (2018) (208)
- From NAFLD to MAFLD: Implications of a Premature Change in Terminology (2020) (203)
- A pilot study of orlistat treatment in obese, non‐alcoholic steatohepatitis patients (2004) (202)
- Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease (2006) (200)
- GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. (2018) (199)
- Non-Alcoholic Steatohepatitis: Effect of Roux-en-Y Gastric Bypass Surgery (2006) (199)
- An assessment by the Statin Liver Safety Task Force: 2014 update. (2014) (197)
- Nonalcoholic steatohepatitis: what we know in the new millennium (2002) (189)
- Diagnosis and therapy of nonalcoholic steatohepatitis. (2008) (188)
- Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. (2004) (186)
- Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes (2017) (175)
- Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12‐month randomized, prospective, open‐ label trial (2011) (171)
- Mixed lineage kinase 3 mediates release of C‐X‐C motif ligand 10–bearing chemotactic extracellular vesicles from lipotoxic hepatocytes (2016) (170)
- Manifestations of chronic hepatitis C virus infection beyond the liver. (2010) (168)
- Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study (2020) (165)
- NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis (2019) (161)
- Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials (2019) (158)
- Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. (2020) (153)
- The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials (2019) (150)
- Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy (2010) (148)
- Effects of Belapectin, an Inhibitor of Galectin-3, in Patients with Nonalcoholic Steatohepatitis With Cirrhosis And Portal Hypertension. (2019) (148)
- Impact of obesity on treatment of chronic hepatitis C (2006) (147)
- Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial (2020) (145)
- A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. (2021) (137)
- The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial (2009) (135)
- A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. (2019) (135)
- Changing Trends in Etiology‐Based and Ethnicity‐Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States (2019) (133)
- NASH and HCC. (2009) (126)
- Vitamin D and nonalcoholic fatty liver disease (NAFLD): Is it more than just an association? (2013) (125)
- Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial (2013) (123)
- Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. (2010) (120)
- Nonalcoholic Steatohepatitis and Noncirrhotic Hepatocellular Carcinoma: Fertile Soil (2012) (120)
- Randomised clinical study: GR‐MD‐02, a galectin‐3 inhibitor, vs. placebo in patients having non‐alcoholic steatohepatitis with advanced fibrosis (2016) (118)
- Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis. (2020) (117)
- Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease (2016) (113)
- Exenatide in the Treatment of Diabetic Patients With Non-Alcoholic Steatohepatitis: A Case Series (2010) (108)
- Effect of Weight Loss, Diet, Exercise, and Bariatric Surgery on Nonalcoholic Fatty Liver Disease. (2016) (107)
- New Advances in Evaluation and Management of Patients with Polycystic Liver Disease (2005) (106)
- A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. (2020) (104)
- Management of hepatitis C virus genotype 4: recommendations of an international expert panel. (2011) (104)
- Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. (2005) (102)
- Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis (2021) (100)
- TEMPORARY REMOVAL: Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study. (2019) (100)
- Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review (2017) (99)
- Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. (2021) (99)
- Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience (2015) (98)
- Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science (2017) (97)
- Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity (2019) (97)
- Orlistat in the Treatment of NASH: A Case Series (2003) (95)
- Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial. (2019) (94)
- Histopathologic variability between the right and left lobes of the liver in morbidly obese patients undergoing Roux-en-Y bypass. (2007) (92)
- Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial (2021) (89)
- Randomized Placebo-Controlled Trial of Emricasan in Non-alcoholic Steatohepatitis (NASH) Cirrhosis with Severe Portal Hypertension. (2019) (87)
- Regenerate: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. (2019) (83)
- Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. (2007) (81)
- Clinical evaluation of a vaccinia‐vectored Hantaan virus vaccine (2000) (81)
- Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis. (2021) (80)
- Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis. (2021) (80)
- Anemia during treatment with peginterferon Alfa‐2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT‐2) trial (2013) (76)
- Liver disease in patients with diabetes mellitus. (2006) (75)
- Diabetic hepatosclerosis: diabetic microangiopathy of the liver. (2006) (75)
- Fat and the liver--a molecular overview. (2002) (75)
- Complex regulation of simple sugar transport in insulin-responsive cells. (1992) (74)
- Insulin resistance among patients with chronic hepatitis C: etiology and impact on treatment. (2008) (73)
- Correlation between insulin resistance and hepatitis C viral load (2006) (72)
- Protein synthesis inhibitors activate glucose transport without increasing plasma membrane glucose transporters in 3T3-L1 adipocytes. (1991) (71)
- Controversies in the Diagnosis and Management of NAFLD and NASH. (2014) (68)
- Insulin resistance and hepatitis C: an evolving story (2011) (66)
- Practice patterns in NAFLD and NASH: real life differs from published guidelines (2016) (66)
- The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic (2015) (64)
- Physical activity: an essential component of lifestyle modification in NAFLD (2012) (64)
- Nonalcoholic fatty liver disease. (2008) (63)
- A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH (2021) (62)
- Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha‐2a plus ribavirin (2012) (61)
- Evidence that functional erythrocyte-type glucose transporters are oligomers. (1991) (61)
- NGM 282 for treatment of non-alcoholic steatohepatitis : a multicentre , randomised , double-blind , placebo-controlled , phase 2 trial (2018) (60)
- Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. (2021) (59)
- Nutrition in cirrhosis and chronic liver disease. (2014) (58)
- Nonalcoholic Fatty Liver Disease Presenting With an Isolated Elevated Alkaline Phosphatase (2006) (58)
- Insulin regulation of hexose transport in mouse 3T3-L1 cells expressing the human HepG2 glucose transporter. (1990) (58)
- Current and emerging therapies in nonalcoholic fatty liver disease. (2008) (57)
- Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (2016) (57)
- Cognitive Lifetime Drinking History in Nonalcoholic Fatty Liver Disease: Some Cases May Be Alcohol Related (2004) (56)
- Is it time to write a prescription for coffee? Coffee and liver disease. (2013) (56)
- Evidence that erythroid-type glucose transporter intrinsic activity is modulated by cadmium treatment of mouse 3T3-L1 cells. (1991) (56)
- Activation of cell surface glucose transporters measured by photoaffinity labeling of insulin-sensitive 3T3-L1 adipocytes. (1992) (55)
- Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. (2019) (55)
- Relation of hemochromatosis with hepatocellular carcinoma: epidemiology, natural history, pathophysiology, screening, treatment, and prevention. (2005) (54)
- MiraLAX is not as effective as GoLytely in bowel cleansing before screening colonoscopies. (2011) (53)
- Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators. (2011) (51)
- Reduced Patient-Reported Outcome Scores Associate with Level of Fibrosis in Patients with Nonalcoholic Steatohepatitis. (2019) (51)
- Hereditary hemochromatosis: update for 2003. (2003) (50)
- Prevalence of colonic adenomas in patients with nonalcoholic fatty liver disease (2011) (50)
- Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial (2018) (50)
- Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005–2016 (2019) (48)
- TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial. (2021) (47)
- qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis (2020) (47)
- A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis. (2021) (46)
- Effect of Weight Loss on Nonalcoholic Fatty Liver Disease (2009) (46)
- Depression is associated with non‐alcoholic fatty liver disease among adults in the United States (2019) (46)
- Pathogenesis of hepatocarcinogenesis in non-cirrhotic nonalcoholic fatty liver disease: Potential mechanistic pathways. (2015) (45)
- Comparison of the natural history of alcoholic and nonalcoholic fatty liver disease (2005) (45)
- HCV in Patients With End-Stage Renal Disease (2008) (43)
- Unconjugated hyperbilirubinemia is inversely associated with non‐alcoholic steatohepatitis (NASH) (2012) (43)
- The European NAFLD registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. (2020) (42)
- Suppressed intrinsic catalytic activity of GLUT1 glucose transporters in insulin-sensitive 3T3-L1 adipocytes. (1991) (42)
- The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. (2018) (42)
- Characterization and Proteome of Circulating Extracellular Vesicles as Potential Biomarkers for NASH (2020) (41)
- Hepatitis C virus infection and nonalcoholic steatohepatitis. (2012) (40)
- The Commensal Microbe V eillonella as a Marker for Response to an FGF19 Analog in NASH (2020) (39)
- Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: still important in the era of direct acting antiviral therapy? (2014) (38)
- Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH (2021) (37)
- Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads. (2010) (37)
- Structure–function studies on nucleoside antibiotic mureidomycin A: synthesis of 5′-functionalised uridine models (1999) (37)
- Interleukin 28B polymorphisms are the only common genetic variants associated with low‐density lipoprotein cholesterol (LDL‐C) in genotype‐1 chronic hepatitis C and determine the association between LDL‐C and treatment response (2012) (35)
- Predictors of nonalcoholic steatohepatitis and significant fibrosis in non‐obese nonalcoholic fatty liver disease (2018) (35)
- Anemia During Treatment With Peginterferon Alfa-2B/Ribavirin With or Without Boceprevir is Associated With Higher SVR Rates: Analysis of Previously Untreated and Previous-Treatment-Failure Patients (2011) (34)
- 476 ANEMIA DURING TREATMENT WITH PEGINTERFERON ALFA-2B/ RIBAVIRIN WITH OR WITHOUT BOCEPREVIR IS ASSOCIATED WITH HIGHER SVR RATES: ANALYSIS OF PREVIOUSLY UNTREATED AND PREVIOUS-TREATMENT-FAILURE PATIENTS (2011) (34)
- NAFLD: Reporting Histologic Findings in Clinical Practice (2021) (34)
- Cardiovascular Disease and Nonalcoholic Fatty Liver Disease: Does Histologic Severity Matter? (2012) (33)
- Review article: nonalcoholic fatty liver disease and hepatitis C virus – partners in crime (2008) (33)
- Nonalcoholic fatty liver disease: Reporting histologic findings in clinical practice. (2020) (32)
- NAFLD: Predictive value of ALT levels for NASH and advanced fibrosis (2013) (32)
- Advances in the Understanding and Treatment of Nonalcoholic Fatty Liver Disease (2012) (31)
- Insulin action on activity and cell surface disposition of human HepG2 glucose transporters expressed in Chinese hamster ovary cells. (1990) (31)
- Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid (2017) (31)
- The Association of Histologic and Non-invasive Tests with Adverse Clinical and Patient-Reported Outcomes in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH). (2020) (31)
- MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis. (2021) (31)
- Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. (2022) (30)
- Elevated urinary bisphenol A levels are associated with non‐alcoholic fatty liver disease among adults in the United States (2019) (30)
- Synthesis of α-substituted vinylsulfonium salts and their application as annulation reagents in the formation of epoxide- and cyclopropane-fused heterocycles. (2014) (30)
- Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients With Primary Biliary Cholangitis (2018) (29)
- Low Thyroid Function in Nonalcoholic Fatty Liver Disease Is an Independent Predictor of All-Cause and Cardiovascular Mortality. (2020) (29)
- Physical Activity, Measured Objectively, is Associated With Lower Mortality in Patients With Nonalcoholic Fatty Liver Disease. (2020) (28)
- Nonalcoholic Steatohepatitis and Endpoints in Clinical Trials. (2016) (28)
- The times they are a-changin' (for NAFLD as well). (2020) (26)
- The Association of Genetic Variants with Hepatic Steatosis in Patients with Genotype 1 Chronic Hepatitis C Infection (2012) (26)
- Trends in hospitalizations for chronic liver disease‐related liver failure in the United States, 2005‐2014 (2019) (26)
- Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis (2021) (26)
- Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH) (2017) (25)
- Nonalcoholic Fatty Liver Disease: Epidemiology, Natural History, and Diagnostic Challenges (2016) (25)
- Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis (2021) (24)
- Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. (2021) (24)
- Noninvasive Markers of Fibrosis and Inflammation in Nonalcoholic Fatty Liver Disease (2016) (23)
- Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis (2019) (23)
- Preparing for the NASH Epidemic: A Call to Action. (2021) (23)
- Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. (2021) (23)
- Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient‐Reported Outcomes (2020) (22)
- Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases (2021) (22)
- Impact of Nonmalignant Portal Vein Thrombosis in Transplant Recipients With Nonalcoholic Steatohepatitis (2019) (22)
- Preparing for the NASH epidemic: A call to action. (2021) (22)
- The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. (2021) (22)
- Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. (2021) (22)
- Efficacy and safety of simtuzumab for the treatment of nonalcoholic steatohepatitis with bridging fibrosis or cirrhosis: results of two phase 2b, dose-ranging, randomized, placebo-controlled trials (2017) (22)
- Hepatitis C virus: a critical appraisal of approaches to therapy. (2009) (21)
- Extrahepatic Manifestations of Hepatitis C (2005) (21)
- New treatments for nonalcoholic fatty liver disease (2006) (21)
- Review of treatment options for nonalcoholic fatty liver disease. (2014) (21)
- Nonalcoholic fatty liver disease: Fibrosis portends a worse prognosis (2015) (20)
- A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes (2021) (20)
- Pharmacologic management of nonalcoholic fatty liver disease. (2004) (19)
- NASH, from diagnosis to treatment: Where do we stand? (2015) (17)
- Hepatic Fat Reduction Due to Resmetirom in Patients with Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life. (2021) (17)
- Effect of NGM 282 , a FGF 19 analogue , in Primary Sclerosing Cholangitis : a Multicentre , Randomized , Double-Blind , Placebo-Controlled Phase 2 Trial (2018) (17)
- Preparation and protonation of [ReBr(N2Ph)2(PPh3)2]. Structure of [ReBr2(NNPh)(NNHPh)(PPh3)2], a complex with a hydrazido(2-) ligand with a large angular distortion (1985) (16)
- Induction of Planar Chirality in Formation of (η5:η1-1-(1-Cyclohexyl-2-(diphenylphosphino)ethyl)indenyl)carbonylrhodium and (η5:η1-1-(2-Phenyl-2- (diphenylphosphino)ethyl)indenyl)carbonylrhodium (2001) (16)
- A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis (2021) (16)
- Nonalcoholic fatty liver disease and elastography: Incremental advances but work still to be done (2016) (16)
- NAFLD‐related hepatocellular carcinoma: The growing challenge (2022) (15)
- Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study. (2010) (15)
- Noninvasive methods of assessing nonalcoholic fatty liver disease: what the clinician needs to know. (2013) (15)
- Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study. (2021) (15)
- Peroxisome proliferator-activated receptors and hepatitis C virus (2011) (14)
- Thiazolidinedione therapy for nonalcoholic steatohepatitis: Go, stop, or proceed with caution? (2010) (14)
- NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a Phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patients (2017) (14)
- Steatosis and chronic hepatitis C infection: mechanisms and significance. (2005) (14)
- Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. (2020) (14)
- Review: Current status of therapy in nonalcoholic fatty liver disease (2009) (14)
- Olanzapine and benztropine as a cause of ischemic colitis in a 27-year-old man. (2012) (13)
- Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease (2021) (13)
- What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond? (2021) (13)
- ACR Appropriateness Criteria radiologic management of hepatic malignancy. (2012) (13)
- High prevalence of hepatic fibrosis in the setting of coexisting diabetes and hepatic steatosis: A case for selective screening in the general population? (2016) (13)
- HCV Replication and Statin Pleotropism: An Adjuvant Treatment Panacea? (2008) (12)
- Changes in Fibrosis, but not the Nafld Activity Score (NAS), are Associated with Disease Progression in Patients with Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis (2017) (11)
- Current treatments in nonalcoholic steatohepatitis (2007) (11)
- Rising Rate of Liver Transplantation in the Baby Boomer Generation with Non-alcoholic Steatohepatitis in the United States (2017) (11)
- Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial. (2022) (11)
- 308 VIROLOGIC AND METABOLIC RESPONSES IN CHRONIC HEPATITIS C (CHC) PATIENTS WITH INSULIN RESISTANCE (IR) TREATED WITH PIOGLITAZONE AND PEGINTERFERON ALFA-2A PLUS RIBAVIRIN (2010) (11)
- The Role of Vitamin E and C Therapy in NASH (2004) (11)
- 730 NASH: clinical assessment of 501 patients from two separate academic medical centers with validation of a clinical scoring system for advanced hepatic fibrosis (2003) (11)
- Small Molecule and Novel Treatments for Chronic Hepatitis C Virus Infection (2007) (10)
- Preparing for the NASH Epidemic: A Call to Action (2021) (10)
- Syphilitic hepatitis uncommon presentation of an old scourge. (2015) (10)
- Nonalcoholic Steatohepatitis: Clinical Presentation, Diagnosis, and Treatment. (2006) (10)
- Nonalcoholic fatty liver disease and fibrosis progression: the good, the bad, and the unknown. (2015) (9)
- Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance (2021) (9)
- Association of Serum Adipocytokines With Insulin Resistance and Liver Injury in Patients With Chronic Hepatitis C Genotype 4 (2012) (9)
- Hepatic progenitor cells: Another piece in the nonalcoholic fatty liver disease puzzle (2012) (8)
- Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score (2022) (8)
- Management of anemia in patients receiving protease inhibitors. (2012) (8)
- Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores. (2022) (8)
- A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. (2022) (8)
- Obesity, insulin resistance, and HCV: Implications for pathogenesis (2005) (7)
- Hepatitis C virus and insulin resistance/diabetes mellitus. (2008) (7)
- Clinical utility of MRI biomarkers for identifying NASH patients' high risk of progression: A multi-center pooled data and meta-analysis. (2021) (7)
- Insulin resistance in chronic hepatitis C, genotypes 1 and 4: The unfortunate reality (2008) (7)
- The role of consensus interferon in the current treatment of chronic hepatitis C viral infection. (2008) (7)
- Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study (2020) (6)
- Il28B Genetic Polymorphism Has Genome Wide Significant Associations with Serum Low Density Lipoprotein Levels and Hepatic Steatosis in Patients with Genotype 1 Chronic Hepatitis C (Chc) (2010) (6)
- Insulin sensitizers in nonalcoholic steatohepatitis (2011) (6)
- Protein and miRNA profile of circulating extracellular vesicles in patients with primary sclerosing cholangitis (2022) (5)
- Nonalcoholic fatty liver disease. (2020) (5)
- Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study (2022) (5)
- NAFLD Review : Diagnosis , Treatment and Outcomes ( Title : 42 characters ) (2015) (5)
- Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies (2012) (5)
- Antiviral Therapy for the Management of Hepatitis C (2005) (5)
- Costs and consequences: Hepatitis C seroprevalence in the military and its impact on potential screening strategies (2016) (5)
- Abnormal liver tests and fatty liver on ultrasound. (2008) (5)
- Utilization of FibroScan Testing in Hepatitis C Virus Management. (2015) (5)
- Improved Ultrasound Attenuation Measurement Method for the Non-invasive Evaluation of Hepatic Steatosis Using FibroScan. (2021) (5)
- The AST to ALT Ratio: A Pattern Worth Considering (2013) (5)
- PREPARATION AND PROTONATION OF (REBR(N2PH)2(PPH3)2). STRUCTURE OF (REBR2(NNPH)(NNHPH)(PPH3)2), A COMPLEX WITH A HYDRAZIDO(2-) LIGAND WITH A LARGE ANGULAR DISTORTION (1985) (4)
- Efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis: 52-week analysis of an ongoing international, randomized, dose ranging phase 2 study. (2018) (4)
- Trends in Liver Transplantation Multiple Listing Practices Associated With Disparities in Donor Availability: An Endless Pursuit to Implement the Final Rule. (2016) (4)
- 1161 ASSOCIATION OF SERUM ADIPOCYTOKINES WITH LIVER INJURY IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 4 (2011) (4)
- 535 Virologic and Metabolic Responses in Chronic Hepatitis C (CHC) Patients With Insulin Resistance (IR) Treated With Pioglitazone and Peginterferon Alfa-2a Plus Ribavirin (2010) (4)
- Vitamin D and NAFLD : Is it More Than Just an Association ? (2013) (4)
- Treatment of nonalcoholic fatty liver disease: Role of dietary modification and exercise (2012) (4)
- Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease (2021) (4)
- NGM282 Significantly Reduces Hepatic Steatosis Independent of Type 2 Diabetes (T2D) Status or Statin Usage—Results from a Phase 2 Trial in Patients with Nonalcoholic Steatohepatitis (NASH) (2018) (3)
- SAT-299-Assessment of NIS4 clinical utility for identification of patients with active NASH (NAS ≥ 4) and significant fibrosis (F ≥ 2) in patients at risk of NASH (2019) (3)
- Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH. (2022) (3)
- Clinical Manifestations and Diagnosis of NAFLD (2007) (3)
- 1160 INSULIN RESISTANCE IN HEPATITIS C GENOTYPE 4 IS PARTIALLY MEDIATED BY VIRUS-SPECIFIC CHANGES IN ADIPOCYTOKINES (2011) (3)
- Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials (2022) (3)
- Serum amyloid A and C-reactive protein diminish after treatment of NASH with rosiglitazone (2003) (3)
- Noninvasive measure of treatment response in non‐alcoholic steatohepatitis: Insights from EMMINENCE and meta‐analysis (2021) (3)
- Same Day Endoscopy and Percutaneous Liver Biopsy: Safety and Cost-Effectiveness (2009) (3)
- Continuous CAP algorithm: reduced variability in a prospective cohort (2020) (3)
- Intensified Peginterferon &agr;-2a Dosing Increases Sustained Virologic Response Rates in Heavy, High Viral Load Hepatitis C Genotype 1 Patients With High Low-density Lipoprotein (2013) (3)
- Performance of noninvasive tests of fibrosis among Asians, Hispanic and non-Hispanic Whites in the STELLAR trials. (2022) (3)
- Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017–2018 (2022) (3)
- 357 - Cenicriviroc Treatment for Adults with Non-Alcoholic Steatohepatitis: Year 2 Analysis of the Phase 2B Centaur Study (2018) (3)
- Su1522 - Proof of Concept Study of an Apoptosis-Signal Regulating Kinase (ASK-1) Inhibitor (Selonsertib) in Combination with an Acetyl-Coa Carboxylase Inhibitor (GS-0976) or a Farnesoid X Receptor (FXR) Agonist (GS-9674) in NASH (2018) (3)
- Editorial: Killing Two Birds With One Stone: Screening for Chronic Hepatitis C at the Time of Colonoscopy in the Baby Boomer Cohort (2013) (3)
- 10 Decline in Hemoglobin Is Associated with Sustained Virologic Response (SVR) Among HCV Genotype 1-Infected Persons Treated with Peginterferon (PEG)/Ribavirin (RBV): Analysis from the Ideal Study (2009) (2)
- Relationship between Baseline Hepatic Disease Severity and the Cardiometabolic and Anti-Inflammatory Effects of Elafibranor in Patients with Non-Alcoholic Steatohepatitis (2016) (2)
- Combination drug therapy allows synergistic therapeutic dose reduction in NASH: a case study of elafibranor (GFT505) and an FXR agonist combination in a model of severe NASH (2017) (2)
- Small steps toward a better treatment for chronic hepatitis C infection: mericitabine, pegylated interferon, and ribavirin in the PROPEL and JUMP‐C trials (2013) (2)
- Do we need a histological score to diagnose non‐alcoholic steatohepatitis? authors’ reply (2011) (2)
- Multifactorial effects of AXA1125 and AXA1957 observed on markers of metabolism, inflammation and fibrosis: a 16-week randomized placebo-controlled study in subjects with non-alcoholic fatty liver disease (NAFLD) with and without type 2 diabetes (T2D) (2020) (2)
- 55 METABOLIC AND ANTI-INFLAMMATORY BENEFICIAL EFFECTS OF PIOGLITAZONE (PIO) TREATMENT IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND THEIR ASSOCIATIONS WITH HISTOLOGICAL IMPROVEMENT (2009) (2)
- Obeticholic acid improves experimental non-invasive markers of non-alcoholic steatohepatitis and advanced fibrosis: a secondary analysis of the phase 3 regenerate study (2020) (2)
- 427 Increase in Liver Transplantation Waitlist Removals Due to Sickness or Death in Patients with Primary Biliary Cirrhosis (2016) (2)
- Expanding the use of the vibration controlled transient elastography in morbid obese patients: validation of a new automated adaptive measurement depths algorithm in a large pooled NAFLD cohort (2020) (2)
- Impaired Fasting Glucose Is Associated With Lower Rates of Sustained Virologic Response (SVR) in Patients With Genotype 1 Chronic Hepatitis C (CHC): Retrospective Analysis of the IDEAL Study (2010) (2)
- High Throughput Screening Assay to Identify Modulators of IL-17 Expression. (2018) (2)
- Inflammatory bowel disease: thinking outside of the intestines (Part 2). (2008) (2)
- FRI-355-Elafibranor, a drug candidate for first line NASH monotherapy and a universal backbone for drug combination treatment (2019) (2)
- Hepatitis B seroprevalence in the U.S. military and its impact on potential screening strategies (2020) (2)
- Insulin resistance in chronic hepatitis C: the search for effective drug treatment continues (2012) (2)
- Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis (2022) (2)
- MRI-AST Score Accurately Predicts Major Adverse Liver Outcome, Hepatocellular Carcinoma, Liver Transplant, and Liver-Related Death. (2023) (2)
- Impact of modest weight reduction on liver histology, portal pressure, and clinical events in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (2017) (2)
- A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis (2022) (2)
- Preparing for the NASH epidemic: A call to action (2021) (2)
- Inflammatory bowel disease: thinking outside of the intestines (Part 1). (2008) (2)
- Liver biopsy versus noninvasive testing in chronic hepatitis C: Where do we stand in 2008? (2008) (2)
- Hepatitis C, insulin resistance, and steatosis (2007) (2)
- Maintaining Patient Safety and Data Integrity of Nonalcoholic Steatohepatitis Clinical Trials During the Severe Acute Respiratory Syndrome–Coronavirus 2 Pandemic (2020) (2)
- 334 OBETICHOLIC ACID IMPROVES EXPERIMENTAL NON-INVASIVE MARKERS OF NON-ALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS; RESULTS OF A SECONDARY ANALYSIS FROM THE MONTH-18 INTERIM ANALYSIS OF THE REGENERATE STUDY (2020) (2)
- HCV therapy in 2006: down with ALT levels, in with awareness of co-existent metabolic syndrome. (2006) (2)
- 15 OPEN-LABEL PROSPECTIVE RANDOMIZED 48 WEEK CLINICAL TRIAL: ROSIGLITAZONE VERSUS ROSIGLITAZONE AND METFORMIN (AVANDAMET) VERSUS ROSIGLITAZONE AND LOSARTAN IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) (2011) (1)
- Metabolic Syndrome and HCV: Where Do We Stand in 2010? (2010) (1)
- Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. (2023) (1)
- Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection. (2016) (1)
- MET409, an optimized farnesoid X receptor agonist, decreased liver fat and improved liver enzymes in patients with non-alcoholic steatohepatitis: a 12-week, randomized, placebo-controlled study (2020) (1)
- Su1521 - Preliminary Efficacy and Safety of Acetyl-Coa Carboxylase (ACC) Inhibitor GS-0976 in Patents with Compensated Cirrhosis due to NASH (2018) (1)
- Is the FIBROSpect II® index effective for determining the stage of fibrosis in patients with chronic hepatitis C? (2008) (1)
- A217 NONINVASIVE ASSESSMENTS TO IDENTIFY PATIENTS WITH ADVANCED FIBROSIS DUE TO NASH: SCREENED POPULATION FROM THE REGENERATE TRIAL (2021) (1)
- Noninvasive Tests (NITs) in the Management of Nonalcoholic Steatohepatitis (NASH) (2020) (1)
- 279-LB: NIS4, a Novel Blood Test, Can Identify "At-Risk" NASH (NAS>4 and Fibrosis>2) in T2D Patients (2019) (1)
- IDDF2019-ABS-0133 Routinely available noninvasive tests discriminate advanced fibrosis due to NASH in the phase 3 STELLAR trials of the ASK1 inhibitor selonsertib (2019) (1)
- Evaluation of PXL065 - Deuterium-Stabilized (R)-Pioglitazone in NASH Patients: a Phase 2 randomized placebo-controlled trial (DESTINY-1). (2023) (1)
- The impact of an educational program on HCV patient outcomes using boceprevir in community practices (OPTIMAL trial) (2015) (1)
- Chapter 28 – Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis (2010) (1)
- Novel protease and polymerase inhibiting agents to treat chronic hepatitis C infection (2008) (1)
- 56th EASD Annual Meeting of the European Association for the Study of Diabetes (2020) (1)
- 304 METABOLIC SYNDROME (MS) IS A NEGATIVE PREDICTOR OF TREATMENT OUTCOME IN PATIENTS WITH CHRONIC HEPATITIS C: RESULTS FROM THE IDEAL STUDY (2010) (1)
- 1450-P: High Risk of Mortality and Disease Progression Associated with Diabetes Mellitus (DM) and Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) in Medicare Patients (2019) (1)
- ALT as a non-invasive biomarker of histological response to pharmacotherapy in NASH patients: insights from the elafibranor GOLDEN505 trial (2016) (1)
- Aldafermin (NGM282) reduces the cross-linked pro-peptides of type III collagen PRO-C3X, a novel biomarker, in non-alcoholic steatohepatitis and primary sclerosing cholangitis patients (2020) (1)
- Correlation between the Hepatic Venous Pressure Gradient and Alpha-Smooth Muscle Actin (SMA) Expression in Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (2016) (1)
- P213 Obeticholic acid improves hepatic fibroinflammation assessed by multiparametric MRI: interim results of the regenerate trial (2020) (1)
- A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis. (2022) (1)
- Corrigendum to "Pharmacotherapy for NASH: Current and emerging" [J Hepatol 68 (2017) 362-375]. (2018) (1)
- Algorithms using noninvasive tests can accurately identify patients with advanced fibrosis due to NASH: data from the STELLAR clinical trials (2019) (1)
- 230 Diabetic hepatosclerosis: perisinusoidal hepatic fibrosis without steatohepatitis among diabetics (2003) (1)
- A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis (2021) (1)
- 977 The presence of severe steatosis or steatohepatitis impairs response to antiviral therapy in patients with chronic hepatitis C (2003) (1)
- Prospective prevalence study of adult NAFLD/NASH utilizing multi-modality imaging compared with liver bopsy (2017) (1)
- Tu1665 OBETICHOLIC ACID IMPROVES HEPATIC FIBROINFLAMMATION AS ASSESSED BY MULTIPARAMETRIC MRI: INTERIM RESULTS OF THE REGENERATE TRIAL (2020) (1)
- Exenatide in the Treatment of Diabetic Patients with Non-Alcoholic Steatohepatitis - A Pilot Study: 2010 Presidential Poster: 242 (2010) (1)
- IDDF2019-ABS-0131 Algorithms using noninvasive tests can accurately identify patients with advanced fibrosis due to NASH: data from the STELLAR clinical trials (2019) (1)
- PC.01.9 EVALUATION OF OBETICHOLIC ACID EFFICACY IN PATIENTS WITH NASH WHO WERE MONITORED USING NONINVASIVE TESTS: A POST HOC ANALYSIS OF THE REGENERATE TRIAL (2021) (1)
- Maintaining Patient Safety and Data Integrity of NASH Clinical Trials During the SARS-CoV-2 Pandemic. (2020) (1)
- 264 INTENSIFIED DOSES OF PEGINTERFERON ALFA-2A AND/OR RIBAVIRIN ARE ASSOCIATED WITH HIGHER RATES OF SVR AND LOWER RELAPSE RATES AMONG PATIENTS WITH METABOLIC SYNDROME (2010) (0)
- Authors’ reply (2009) (0)
- Lamivudine Monotherapy in Decompensated Cirrhosis Due to HBeAg Negative Chronic HBV Infection (2004) (0)
- PORTAL HYPERTENSION. NOT ALWAYS DUE TO CIRRHOSIS: 638 (2004) (0)
- Incidence and risk factors for cardiovascular events in patients with advanced fibrosis due to non-alcoholic steatohepatitis: data from the phase 3 STELLAR trials (2020) (0)
- Single‐center Experience with Gastrointestinal Bleeding in Patients Taking the New Oral Direct Thrombin Inhibitor Dabigatran: 1637 (2013) (0)
- Pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis (FALCON 1): a randomized phase 2b study. (2023) (0)
- Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH (2022) (0)
- Abstract #423 Baseline Characteristics of Patients with and Without Diabetes in Trials for Advanced Fibrosis/Cirrhosis Due to Nonalcoholic Steatohepatitis (Nash) (2019) (0)
- SEVERITY OF BIOPSY-PROVEN NAFLD NOT PREDICTIVE OF PRESENCE OR SEVERITY OF CORONARY ATHEROSCLEROSIS IN ASYMPTOMATIC PATIENTS: RESULTS FROM THE PROSPECTIVE PREVALENCE STUDY (2018) (0)
- Occurrence of noncirrhotic HCC in NAFLD (2016) (0)
- Erratum to: The Association of Genetic Variants with Hepatic Steatosis in Patients with Genotype 1 Chronic Hepatitis C Infection (2012) (0)
- 354 - Prevalence and Stratification of NAFLD/NASH in a UK and US Cohort Using Non-Invasive Multiparametric MRI (2018) (0)
- Early Cardiac Dysfunction in Biopsy-proven Nonalcoholic Fatty Liver Disease. (2021) (0)
- The Non-Alcoholic Steatohepatitis and Cardiovascular Disease Intersection, an Important Consideration in Drug Development (2020) (0)
- Lack of reliability of liver biopsies in non-alcoholic steatohepatitis (NASH) clinical trials - potential implications for developing new therapies for NASH (2020) (0)
- NRPT reduces markers of hepatic inflammation in non-alcoholic fatty liver disease: a double-blind, placebo-controlled clinical trial. (2022) (0)
- T06.01.12 OBETICHOLIC ACID (OCA) IMPROVES NON-INVASIVE MARKERS OF FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH): A SECONDARY ANALYSIS OF THE PHASE 3 REGENERATE STUDY (2020) (0)
- 1876-P: Impact of Diabetes on Liver Disease Progression in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH) (2019) (0)
- Sa1537 Current Trends in Liver Transplantation Among HCV-Infected Baby Boomer Generation in the United States (2016) (0)
- 292 IMPACT OF HIGHER DOSES OF PEGINTERFERON ALFA-2A AND RIBAVIRIN ON RVR, CEVR AND SVR IN HCV G1 PATIENTS WITH VIRAL LOADS ≥400,000 IU/ML WEIGHING ≥85 kg (2010) (0)
- Su1541 - Responsiveness of Controlled Attenuation Parameter (CAP) and Its Correlation with Magnetic Resonance Imagingproton Density Fat Fraction (MRI-PDFF) in a Multi-Center Clinical Trial of Subjects with Nonacoholic Steatohepatitis (NASH) (2018) (0)
- 116-LB: Efruxifermin Is Associated with Improved Glucose Metabolism in Patients with NASH and Type 2 Diabetes (2021) (0)
- The FGF19 analogue aldafermin improves non-invasive tests in patients with non-alcoholic steatohepatitis (2020) (0)
- STRUCTURAL AND FUNCTIONAL CHANGES BY 3-DIMENSIONAL (3D) TRANSTHORACIC ECHOCARDIOGRAPHY AND GLOBAL LONGITUDINAL STRAIN IN ASYMPTOMATIC PATIENTS WITH BIOPSY-PROVEN NAFLD: RESULTS FROM THE PROSPECTIVE PREVALENCE STUDY (2019) (0)
- 27 – Management of Nonalcoholic Fatty Liver Disease and Metabolic Syndrome (2018) (0)
- FibroScan-based score to identify patients with non-alcoholic steatohepatitis: development in a multi-centric British cohort and validation in a large American cohort (2017) (0)
- Nonalcoholic Fatty Liver Disease: Clinical Features, Disease Modifiers, and Natural History (2016) (0)
- Paper alert. (2020) (0)
- Synthesis of α‐Substituted Vinylsulfonium Salts and Their Application as Annulation Reagents in the Formation of Epoxide‐ and Cyclopropane‐Fused Heterocycles. (2015) (0)
- Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: independent validation of the Agile 3+ and 4 scores (2023) (0)
- Reply to: Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back? (2021) (0)
- H. pylori and platelet counts (2006) (0)
- P1031 : Comparison of clinical, biochemical, and histopathological profiles between NAFLD in Asian-Indians and United Atates adults (2015) (0)
- The Pointy End of the NAFLD Iceberg: Cirrhosis, Portal Hypertension, and Liver Failure (2013) (0)
- 431 SVR RATES ARE HIGHER AMONG HCV G1 PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN (LDL) LEVELS WHEN TREATED WITH INTENSIFIED DOSES OF PEGINTERFERON ALFA-2A (PEGASYS®) PLUS RIBAVIRIN (2011) (0)
- Rencofilstat, a cyclophilin inhibitor: A phase 2a, multicenter, single‐blind, placebo‐controlled study in F2/F3 NASH (2022) (0)
- Sa1686 Galectin-3 (Gal-3) Expression in Relation to Fibrosis in Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) (2014) (0)
- CLINICAL — LIVER Ela fi branor, an Agonist of the Peroxisome Proliferator L Activated Receptor L a and L d , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening (0)
- 13C-Methacetin Breath Test accurately assesses clinically significant portal hypertension in patients with NASH cirrhosis (2017) (0)
- Obeticholic acid (OCA) improves non-invasive markers of fibrosis in patients with non-alcoholic steatohepatitis (NASH): a secondary analysis of the phase 3 Regenerate study (2020) (0)
- Su1348: EFFICACY, SAFETY, AND TOLERABILITY OF SELADELPAR IN PATIENTS WITH COMPENSATED LIVER CIRRHOSIS DUE TO PRIMARY BILIARY CHOLANGITIS (PBC); A POOLED ANALYSIS OF PHASE 2 AND PHASE 3 STUDIES (2022) (0)
- AF.81 NONINVASIVE ASSESSMENTS TO IDENTIFY PATIENTS WITH ADVANCED FIBROSIS DUE TO NASH: SCREENED POPULATION FROM THE REGENERATE TRIAL (2021) (0)
- 326 OBESITY-SPECIFIC HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS: RESULTS FROM THE REGENERATE STUDY (2020) (0)
- O26 Obeticholic acid improves experimental noninvasive markers of nonalcoholic steatohepatitis and advanced fibrosis: results from regenerate (2021) (0)
- S1178 Utility and Interpretation of the Quantitative MRI Metrics PDFF and cT1 as Biomarkers for Non-Alcoholic Steatohepatitis (2020) (0)
- Obeticholic acid demonstrates sustained improvements at month 24 in transaminases and non-invasive markers of fibrosis: Results of a post hoc analysis from the interim analysis of the REGENERATE study (2020) (0)
- Validity of the Non-Alcoholic Fatty Liver Disease Activity Score (NAS): Comparing the Nas With Pathology Diagnosis (2011) (0)
- A Phase 2, Randomized Controlled Trial of Berberine Ursodeoxycholate (BUDCA) in Patients with Presumed Non-Alcoholic Steatohepatitis (NASH) and Type 2 Diabetes (2021) (0)
- Obeticholic acid (OCA) improves experimental non-invasive markers of NASH and advanced fibrosis: results of a secondary analysis from the month-18 interim analysis of the REGENERATE study (2020) (0)
- 119-LB: Increased Adiponectin following Efruxifermin Treatment Is Associated with Improvements in Dyslipidemia, Glucose Metabolism, and Liver Health in a 16-Week, Randomized, Placebo-Controlled NASH Trial (2021) (0)
- Crystal structure of 1-((2-fluoro-4-(3-(trifluoromethyl)-4,5,6,7- tetrahydro-1H-indazol-1-yl)phenyl)methyl)-2-pyrrolidinone in complex with the ligand binding domain of the Rat GluA2 receptor and glutamate at 2.2A resolution. (2011) (0)
- Chronic HCV and Steatosis (2012) (0)
- Prevalence of Liver Cancer in Hereditary Hemochromatosis and Associated Outcomes: A Propensity-Matched Analysis (2021) (0)
- Biomarkers, Imaging, and Safety in a Well-compensated NASH Cirrhotic Cohort Treated With Resmetirom, a Thyroid Hormone Receptor-beta Selective Agonist, for 52 Weeks (2023) (0)
- Reply: (2009) (0)
- Comprar Non-Alcoholic Steatohepatitis, An Issue of Clinics in Liver Disease | Stephen A. Harrison | 9781437712377 | Saunders (2009) (0)
- Reply: (2009) (0)
- BIOCHEMICAL MARKERS OF LIPID PEROXIDATION AND FIBROSIS IN PATIENTS WITH SIMPLE STEATOSIS AS COMPARED TO PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS: 279 (2004) (0)
- Mo1551 Current Trends in NASH-Related Liver Transplantation in the United States: Baby Boomer Generation at Highest Risk (2016) (0)
- A Randomized, Dose-Finding, Proof-of-Concept Study of Berberine Ursodeoxycholate in Patients With Primary Sclerosing Cholangitis (2022) (0)
- Challenges and opportunities in NASH drug development (2023) (0)
- Genome-Wide Association Study of Clinically Significant Portal Hypertension in Patients with Nonalcoholic Steatohepatitis and Advanced Fibrosis (2016) (0)
- 135-OR: A Novel Thiazolidinedione (TZD) with Minimal PPAR-γ Activity Maximized for Mitochondrial Pyruvate Carrier (MPC) Modulation: Six-Month Analysis of Glycemia in a 12-Month Nonalcoholic Steatohepatitis (NASH) Study (2019) (0)
- Hepatitis C Therapy in Community Practice (OPTIMAL): An Educational Partnership Program between Academic and Community Practices: 408 (2013) (0)
- Structure—Function Studies on Nucleoside Antibiotic Mureidomycin A: Synthesis of 5′‐Functionalized Uridine Models. (1999) (0)
- Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens (2012) (0)
- PNPLA3 Variants Confer an Increased Risk of Advanced Fibrosis Due to Non-Alcoholic Steatohepatitis (2016) (0)
- Nonalcoholic fatty liver disease: is it all in the genes? (2010) (0)
- Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection. (2016) (0)
- Obesity-specific health-related quality of life in patients with non-alcoholic steatohepatitis: results from the regenerate study (2020) (0)
- HMG-COA REDUCTASE INHIBITORS (STATINS) AND METFORMIN ARE ASSOCIATED WITH PRESERVATION OF HEPATIC FUNCTION AND LESS PORTAL-SYSTEMIC SHUNTING IN ADVANCED CHRONIC LIVER DISEASE (2021) (0)
- Diagnostic accuracy of acoustic radiation force impulse elastography for the staging of hepatic fibrosis in non-alcoholic fatty liver disease: a systematic review and meta-analysis (2020) (0)
- 278-LB: Type 2 Diabetes (T2D) as a Risk Factor for NASH and Significant Liver Fibrosis (F>2) in an International Cohort of 2,363 Patients with Metabolic Steatosis (2019) (0)
- Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis (2023) (0)
- 686 EFFECTS ON PRURITUS AND SLEEP DISTURBANCE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) AFTER 1 YEAR OF TREATMENT WITH SELADELPAR, A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA AGONIST: RESULTS OF AN OPEN-LABEL PHASE 2 STUDY (2020) (0)
- Crystal structure of N,N-dimethyl-4-(3-(trifluoromethyl)-4,5,6,7- tetrahydro-1H-indazol-1-yl)benzamide in complex with the ligand binding domain of the Rat GluA2 receptor and glutamate at 2.2A resolution. (2011) (0)
- LIVRQNac (AXA1125) ENHANCES INSULIN SENSITIVITY IN PRIMARY HUMAN HEPATOCYTES AND IN SUBJECTS WITH NAFLD AND T2D (2021) (0)
- 752-P: LIVRQNac (AXA1125) Enhances Insulin Sensitivity in Primary Human Hepatocytes and in Subjects with NAFLD and T2D (2021) (0)
- Overview of Clinical Treatment Trials for NASH (2017) (0)
- Crystal structure of 1-(4-(2-oxo-2-(1-pyrrolidinyl)ethyl)phenyl)-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazole in complex with the ligand binding domain of the Rat GluA2 receptor and glutamate at 1.5A resolution. (2011) (0)
- Su1546 - Early Cardiac Dysfunction in Biopsy-Proven Nonalcoholic Fatty Liver Disease (NAFLD) (2018) (0)
- Crystal structure of 1-((4-(3-(trifluoromethyl)-6,7-dihydropyrano(4,3- c(pyrazol-1(4H)-yl)phenyl)methyl)-2-pyrrolidinone in complex with the ligand binding domain of the Rat GluA2 receptor and glutamate at 1.6A resolution. (2011) (0)
- 1292 GILBERT'S SYNDROME AND NASH: A PROTECTIVE EFFECT OF UNCONJUGATED HYPERBILIRUBINEMIA (2012) (0)
- Comparison of Clinical, Biochemical, and Histopathologic Profiles between NAFLD in Asian-Indians and United States Adults (2022) (0)
- S1186 Evaluation of the FAST Score as a Predictor of Fibrotic NASH in Hispanics (2021) (0)
- T1990 Peginterferon Alfa-2a (40KD) Has a Wide Safety Margin in Patients Infected With Hepatitis C Virus Genotype 1: Pooled Data From Four Randomized Multicenter Studies (2010) (0)
- Management of Lysosomal Acid Lipase Deficiency for the Gastroenterologist and Hepatologist. (2016) (0)
- 232 Mixed Lineage Kinase 3 Mediates the Release of Proinflammatory Extracellular Vesicles in Nonalcoholic Steatohepatitis (2015) (0)
- Table of contents (2016) (0)
- 531 High Dose Combination Therapy (Peginterferon Alfa-2a Plus Ribavirin) in Difficult-to-Cure Patients With Chronic Hepatitis C: Impact on Rvr, Cevr and SVR (2010) (0)
- NASH Cirrhosis Trials And Major Adverse Liver Outcomes: Big Data Needed. (2022) (0)
- Overview of Current and Emerging Therapeutic Approaches to Nonalcoholic Steatohepatitis. (2018) (0)
- Mo1383: SEQUENTIAL TESTING FOR HIGH-RISK NASH BY CT1 FROM LIVERMULTISCAN IMPROVES DIAGNOSTIC YIELD COMPARED TO THE USE OF MRE ALONE (2022) (0)
- Current Treatments in Current Treatments in Nonalcoholic Steatohepatitis Nonalcoholic Steatohepatitis (2007) (0)
- 1090-P: MSDC-0602k, a New Oral Insulin Sensitizer in Insulin Resistant NASH Patients with and without Type 2 Diabetes (T2D) (2020) (0)
- Prospective Comparison to Liver Biopsy of Controlled Attenuation Parameter and Proton Density Fat Fraction for Predicting Degree of Steatosis in Non-Alcoholic Fatty Liver Disease (2016) (0)
- Clinical Trial Landscape in NASH. (2023) (0)
- Diagnostic accuracy of magnetic resonance elastography for the staging of fibrosis and diagnosis of steatohepatitis in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis (2020) (0)
- Boceprevir (BOC) in Community Practice: Interim Results on Early Response and Safety from the OPTIMAL Trial: 406 (2013) (0)
- Graft Outcomes in Kidney Transplantation Alone with Concomitant Cirrhosis (2016) (0)
- 293 PREDICTORS OF RELAPSE AMONG PATIENTS TREATED WITH STANDARD OR INDUCTION DOSE PEGINTERFERON ALFA-2A (40KD) COMBINED WITH STANDARD OR HIGHER DOSE RIBAVIRIN IN DIFFICULT-TO-CURE PATIENTS (2010) (0)
- Obeticholic Acid Efficacy in Patients With NASH Monitored Using Noninvasive Tests: Post Hoc Analysis of REGENERATE Trial (2021) (0)
- Noninvasive Diagnostic Approach to NASH: Radiological Diagnostics (2020) (0)
- Obeticholic acid improves hepatic fibroinflammation as assessed by multiparametric magnetic resonance imaging: interim results of the regenerate trial (2020) (0)
- An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography. (2023) (0)
- Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): a randomized phase 2b study. (2023) (0)
- Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis (2020) (0)
- Serum levels of miR-34a to rule-out NAFLD in healthy subjects and identify NAFLD patients with active NASH (NAS>= 4) and significant liver fibrosis (F >= 2) (2020) (0)
This paper list is powered by the following services:
Other Resources About Stephen Harrison
What Schools Are Affiliated With Stephen Harrison ?
Stephen Harrison is affiliated with the following schools:
